Bellicum Weighs Options After Serious Safety Concerns Halt Only Trials

Bellicum Pharmaceuticals has ended the only clinical trials evaluating its GoCAR-T cell product in combination with rimiducid following serious safety concerns.

The Houston-based biotech has discontinued testing for GoCAR-T BPX-601 and BPX-603 after the most recent patient treated with BPX-601 experienced serious immune-mediated adverse events.